Pharmacophore development and SAR studies of imidazoline receptor ligands

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1542-1555

  Nikolic, Katarina ^a   Agbaba, Danica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

I1 imidazoline receptors; I2 imidazoline receptors; I3 imidazoline receptors

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BRIMONIDINE; CLONIDINE; IDAZOXAN; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; RILMENIDINE; TRACIZOLINE;

BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG SELECTIVITY; HUMAN; PHARMACOPHORE; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; DRUG DISCOVERY; HUMANS; IMIDAZOLINE RECEPTORS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873156974     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712803832636     Document Type: Review

References (150)

1. Schmitt, H.; Boissier, J.R.; Giudicelli, J.F.; Fichelle, Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 115). II. Central sympathetic structures. Eur. J. Pharmacol., 1968, 2 (5), 340-346.
2. Schmitt, H.; Fenard, S. Action of alpha-adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittel-Forschung, 1973, 23, 40-45.
3. Bousquet, P.; Schwartz, J. Alpha-adrenergic drugs. Pharmacological tools for the study of the central vasomotor control. Biochem. Pharmacol., 1983, 32, 1459-65.
4. Bousquet, P.; Feldman, J.; Schwartz, J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther., 1984, 230, 232-236.
5. Ernsberger, P.; Guiliano, R.; Willette, R.N.; Reis, D.J. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J. Pharmacol. Exp. Ther., 1990, 253: 408-418.
6. Mayorov, D.N.; Burke, S.L.; Head, G.A. Relative importance of rostral ventrolateral medulla in sympathoinhibitory action of rilmenidine in conscious and anesthetized rabbits. J. Cardiovasc. Pharmacol., 2001, 37, 252-261.
7. Mayorov, D.; Chernobelski, M.; Medvedev, O. Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. J. Cardiovasc. Pharmacol., 1993, 22, 314-320.
8. Bruban, V.; Estato, V.; Schann, S.; Ehrhardt, J.D.; Monassier, L.; Renard, P.; Scalbert, E.; Feldman, J.; Bousquet, P. Evidence for synergy between 2-adrenergic and nonadrenergic mechanisms in central blood pressure regulation. Circulation, 2002, 105, 1116-1121.
9. Hieble, J.P.; Ruffolo, R.R., Jr. Possible Structural and Functional Relationships between Imidazoline Receptors and 2-Adrenoceptors. Ann. N. Y. Acad. Sci., 1995, 763, 8-21.
10. Regunathan, S.; Reis, D.J. Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol., 1996, 36: 511-544.
11. Ruiz, J.; Barinagarrementeria, G.; Martín-Gómez, J.I.; Callado, L.F.; Meana, J.J., Characterization of [3H]idazoxan binding sites on human platelets. Platelets, 2002, 13, 241-246.
12. Bousquet, P.; Bricca, G.; Dontenwill, M.; Feldman, J.; Greney, H.; Belcourt, A.; Stutzmann, J.; Tibirica, E. From the 2-adrenoceptors to the imidazoline preferring receptors. Fundam. Clin. Pharmacol., 1992, 6 (Suppl 1), 15S-21S.
13. Head, G.A.; Mayorov, D.N. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc. Hematol. Agents Med. Chem., 2006, 4, 17-32.
14. Chan, C.K.S.; Burke, S.L.; Head, G.A. Contribution of imidazoline receptors and 2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine. J. Hypertension, 2007, 25, 147-155.
15. Tibirica, E.; Feldman, J., Bousquet, P. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J. Pharmacol. Exp. Ther., 1988, 244, 1062-1066.
16. Delbarre, B.; Schmitt, H. Sedative effects of β-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Eur. J. Pharmacol., 1971, 13: 356-363.
17. De Sarro, G.B.; Ascioti, C.; Froio, F.; Libri, V.; Nistico, G. Evidence that locus coeruleus is the site where clonidine and drugs acting at 1-and 2-adrenoceptors affect sleep and arousal mechanisms. Br. J. Pharmacol., 1987, 90, 675-685.
18. Head, G.A.; Chan, C.K.S.; Burke, S.L. Relationship between imidazoline and 2-adrenoceptors involved in the sympathoinhibitory actions of centrally acting antihypertensive agents. J. Auton. Nerv. Syst., 1998, 72, 163-169.
19. Hein, L. Limbird, L.E.; Eglen, R.M.; Kobilka, B.K. Gene substitution/knock-out to delineate the role of the 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines. Ann. N Y Acad. Sci., 1999, 881, 265-271.
20. Talentino-Silva, F.P.; Haxiu, M.A., Waldbaum, S., Breshaj, I.A.; Ernsberger, P. Alpha2-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice. Brain Res., 2000, 862, 26-35.
21. Bruban, V.; Feldman, J.; Greney, H. et al. Respective contributions of β-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs. Br. J. Pharmacol., 2001, 133, 261-266.
22. Schann, S.; Bruban, V.; Pompermayer, K.; Feldman, J.; Pfeiffer, B.; Renard, P.; Scalbert, E.; Bousquet, P.; Ehrhardt, J-D. Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activity. J. Med. Chem., 2001, 44, 1588-1593.
23. Urosevic, D.; Schann, S.; Ehrhardt, J-D.; Bousquet, P.; Greney, H. LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors. Br. J. Pharmacol., 2004, 142, 609-617.
24. Greney, H.; Urosevic, D.; Schann, S.; Dupuy, L.; Bruban, V.; Ehrhardt, J-D.; Bousquet, P.; Dontenwill, M. [125I]2-(2-Chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), a High-Affinity Radioligand Selective for I1 Imidazoline Receptors. Mol. Pharmacology, 2002, 62, 181-191.
25. Piletz, J.E.; Andorn, A.C.; Unnerstall, J.R.; Halaris, A. Binding of [3H]-p-aminoclonidine to 2-adrenoceptor states plus a nonadrenergic site on human platelet plasma membranes. Biochem. Pharmacol., 1991, 42, 569-584.
26. Heemskerk, F.M.; Dontenwill, M.; Greney, H.; Vonthron, C.; Bousquet, P. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem, J. Neurochem., 1998, 71, 2193-2202.
27. Ernsberger, P.; Shen, I.H. Membrane localization and guanine nucleotide sensitivity of medullary I1 imidazoline binding sites. Neurochem. Int., 1997, 30, 17-23.
28. Dontenwill, M.; Vonthron, C.; Greney, H.; Magnier, C., Heemskerk, F.; Bousquet, P. Identification of human I1 receptors and their relationship to 2-adrenoceptors. Ann. N Y Acad. Sci., 1999, 881, 123-135.
29. Molderings, G.J.; Moura, D.; Fink, K.; Bonisch, H.; Gothert, M. Binding of [3H] clonidine to I1-imidazoline sites in bovine adrenal medullary membranes. Naunyn-Schmiedeberg's Arch. Pharmacol., 1993, 348, 70-76.
30. Ernsberger, P.; Piletz, J.E.; Graff, L.M.; Graves, M.E. Optimization of radioligand binding assays for I1-imidazoline sites. Ann. N. Y. Acad. Sci., 1995, 763, 163-168.
31. Separovic, D.; Kester, M.; Ernsberger, P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol. Pharmacol., 1996, 49, 668-675.
32. Greney, H.; Ronde, P.; Magnier, C.; Maranca, F.; Rascente, C.; Quaglia, W.; Giannella, M.; Pigini, M.; Brasili, L.; Lugnier, C.; Bousquet, P.; Dontenwill, M. Coupling of I1-imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline. Mol. Pharm., 2000, 57, 1142-1151.
33. Gentili, F.; Bousquet, P.; Brasili, L.; Dontenwill, M.; Feldman, J.; Ghelfi, F.; Giannella, M.; Piergentili, A.; Quaglia, W.; Pigini, M. Imidazoline Binding Sites (IBS) Profile Modulation: Key Role of the Bridge in Determining I1-IBS or I2-IBS Selectivity within a Series of 2-Phenoxymethylimidazoline Analogues. J. Med. Chem., 2003, 46, 2169-2176.
34. Piletz, J.E.; Sletten, K. Nonadrenergic imidazoline binding sites on human platelets. J. Pharmacol. Exp Ther., 1993, 267, 1493-1502.
35. Felsen, D.; Ernsberger, P.; Sutaria, P.M.; Nejat, R.J.; Nguyen, P.; May, M.; Breslin, D.S.; Marion, D.N.; Vaughan, D. Jr. Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate. J. Pharmacol. Exp. Ther., 1994, 268, 1063-1071.
36. Separovic, D.; Kester, M.; Haxhiu, M.A.; Ernsberger, P. Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res., 1997, 749, 335-339.
37. Zhang, J.; El Mas, M.M.; Abdel-Rahman, A.A. Imidazoline I(1) receptorinduced activation of phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells. Eur. J. Pharmacol., 2001, 415, 117-125.
38. Zhang, J.; Abdel-Rahman, A.A. Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (I1)-receptor-mediated hypotension. J. Pharmacol. Exp Ther., 2005, 314, 945-952.
39. Edwards, L.; Fishman, D.; Horowitz, P.; Bourbon, N.; Kester, M.; Ernsberger, P. The I(1)-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J. Neurochem., 2001, 79, 931-940.
40. Edwards, L.; Ernsberger, P. The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase. Brain Res., 2003, 980, 71-79.
41. Ernsberger, P. The I(1)-imidazoline receptor and its cellular signaling pathways. Ann. N. Y. Acad. Sci., 1999, 881, 35-53.
42. Piletz, J.E.; Ivanov, T.R.; Sharp, J.D. Ernsberger, P.; Chang, C.H.; Pickard, R.T.; Gold, G.; Roth, B.; Zhu, H.; Jones, J.C.; Baldwin, J.; Reis, D.J. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol., 2000, 19, 319-329.
43. Dontenwill, M.; Piletz, J.E.; Chen, M.; Baldwin, J.; Pascal, G.; Ronde, P.; Dupuy, L.; Greney, H.; Takeda, K.; Bousquet, P. IRAS is an anti-apoptotic protein. Ann. NY Acad. Sci., 2003, 1009, 400-412.
44. Alahari, S.K.; Lee, J.W.; Juliano, R.L. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J. Cell Biol., 2000, 151, 1141-1154.
45. Piletz, J.E.; Wang, G.; Zhu, H. Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue. Ann. N.Y. Acad. Sci., 2003b, 1009, 392-399.
46. Molderings, G.J.; Bönisch, H.; Brüss, M.; Wolf, C., von Kügelgen, I.; Göthert, M. S1P-receptors in PC12 and transfected HEK293 cells: Molecular targets of hypotensive imidazoline I1 receptor ligands. Neurochem. Int., 2007, 51, 476-485
47. Zhang, J.; Abdel-Rahman, A.A. Nischarin as a functional imidazoline (I1) receptor. FEBS Letters, 2006, 580, 3070-3074.
48. Li, F.; Wu, N.; Su, R.B.; Zheng, J.Q.; Xu, B.; Lu, X.Q.; Cong, B.; Li, J. Involvement of Phosphatidylcholine-Selective Phospholipase C in Activation of Mitogen-Activated Protein Kinase Pathways in Imidazoline Receptor Antisera-Selected Protein. J. Cell. Biochem., 2006, 98, 1615-1628.
49. Sun, Z.; Chang, Ch.H.; Ernsberger, P. Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells. J. Neurochem., 2007, 101, 99-108.
50. Alahari, S.K. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp. Cell Res., 2003, 288, 415-424.
51. Baranwal, S.; Wang, Y.; Rathinam, R.; Lee, J.; Jin, L.; McGoey, R.; Pylayeva, Y.; Giancotti, F.; Blobe, G.C.; Alahari, S.K.; Molecular Characterization of the Tumor-Suppressive Function of Nischarin in Breast Cancer. J. Natl. Cancer. Inst., 2011, Sep 14. Epub ahead of print.
52. Meeley, M.P.; Ernsberger, P.R.; Granata, A.R.; Reis, D.J. An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci., 1986, 38, 1119-1126.
53. Bricca, G.; Dontenwill, M.; Molines, A.; Feldman, J.; Belcourt, A.; Bousquet, P. Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem. Eur. J. Pharmacol., 1988, 150, 401-402.
54. Tesson, F.; Prip-Buus, C., Lemoine, A.; Pegorier, J.P.; Parini, A. Subcellular distribution of imidazolineguanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. J. Biol. Chem., 1991, 266, 155-160.
55. Holt, A.; Wieland, B.; Baker, G.B. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br. J. Pharmacol., 2004, 143, 495-507.
56. Limon, I.; Coupry, I.; Lanier, S.M.; Parini, A. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. J. Biol. Chem., 1992, 267, 21645-21649.
57. Wang, H.; Regunathan, S.; Meeley, M.P.; Reis, D.J. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. Mol. Pharmacol., 1992, 42, 792-801.
58. Kimura, A.; Tyacke, R.J.; Robinson, J.J.; Husbands, S.M.; Minchin, M.C.W.; Nutt, D.J.; Hudson, A.L. Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site. Brain Research, 2009, 1279, 21-28.
59. Finn, D.P.; Marti, O.; Harbuz, M.S.; Valles, A.; Belda, X.; Marquez, C., Jessop, D.S.; Lalies, M.D.; Armario, A.; Nutt, D.J., Hudson, A.L. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl), 2003, 167, 195-202.
60. Halaris, A.; Piletz, J.E. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann. NY Acad. Sci., 2003, 1009, 1-20.
61. Jackson, H.C.; Griffin, I.J.; Nutt, D.J. The effects of idazoxan and other alpha 2-adrenoceptor antagonists on food and water intake in the rat. Br. J. Pharmacol., 1991, 104, 258-262.
62. Polidori, C.; Gentili, F.; Pigini, M., Quaglia, W., Panocka, I.; Massi, M. Hyperphagic effect of novel compounds with high affinity for imidazoline I(2) binding sites. Eur. J. Pharmacol., 2000, 392, 41-49.
63. Diaz, A.; Mayet, S.; Dickenson, A.H. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur. J. Pharmacol., 1997, 333, 9-15.
64. Jett, M.F.; Hedley, L.R.; Dillon, M.P.; Eglen, R.M.; Hunter, J.C. Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats. Ann. NY Acad. Sci., 1999, 881, 369-371.
65. Martin-Gomez, J.I.; Ruiz, J.; Callado, L.F.; Garibi, J.M.; Aguinaco, L.; Barturen, F.; Javier Meana, J. Increased density of I2-imidazoline receptors in human glioblastomas. Neuroreport, 1996, 7(8), 1393-1396.
66. Eglen, R.M.; Hudson, A.L.; Kendall, D.A.; Nutt, D.J.; Morgan, N.G.; Wilson, V.G.; Dillon, M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci., 1998, 19, 381-390.
67. Morgan, N.G.; Chan, S.L. Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues? Curr. Pharm. Des., 2001, 7, 1413-1431.
68. Clews, J.; Morgan, N.G.; Ramsden, C.A. Preparation of the I3 imidazoline receptor antagonist KU14R and related 2,3-dihydrobenzo[b]furan derivatives. Synthesis, 2001, 10, 1546-1550.
69. Li, G.; Regunathan, S.; Barrow, C.J.; Eshraghi, J.; Cooper, R.; Reis, D.J. Agmatine: An endogenous clonidine-displacing substance in the brain. Science, 1994, 263, 966-969.
70. Prell, G.D.; Martinelli, G.P.; Holstein, G.R.; Matulic-Adamic, J.; Watanabe, K.A.; Chan, S.L.; Morgan, N.G.; Haxhiu, M.A.; Ernsberger, P. Imidazoleacetic acid-ribotide: an endogenous ligand that stimulates imidazol(in)e receptors. Proc. Natl Acad. Sci. USA, 2004, 101, 13 677-682.
71. Halaris, A.; Plietz, J. Agmatine: Metabolic pathway and spectrum of activity in brain. CNS Drugs, 2007, 21, 885-900.
72. Husbands, S.M.; Glennon, R.A.; Gorgerat, S., Gough, R., Tyacke, R.; Crosby, J.; Nutt, D.J.; Lewis, J.W., Hudson, A.L. Betacarboline binding to imidazoline receptors. Drug Alcohol Depend., 2001, 64, 203-208.
73. Musgrave, I.F.; Badoer E. Harmane produces hypotension following microinjection into the RVLM: possible role of I1-imidazoline receptors. Br. J. Pharmacol., 2000, 129, 1057-1059.
74. Parker, Ch.A.; Anderson, N.J.; Robinson, E.S.J.; Price, R.; Tyacke, R.J.; Husbands, S.M.; Dillon, M.P.; Eglen, R.M.; Hudson, A.L.; Nutt, D.J.; Crump, M.P.; Crosby, J. Harmane and Harmalan Are Bioactive Components of Classical Clonidine-Displacing Substance. Biochemistry, 2004, 43, 16385-16392.
75. Piletz, J.E.; Zhu, H.; Chikkala, D.N. Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J. Pharmacol. Exp. Ther., 1996, 279(2), 694-702.
76. Nikolic, K.; Agbaba, D. Imidazoline Antihypertensive Drugs: Selective I1-Imidazoline Receptors Activation. Cardiovascular Therapeutics, (2011) 1-8. doi: 10.1111/j.1755-5922.2011.00269.x. Article first published online: 23 march 2011.
77. Anastassiadou, M.; Danoun, S.; Cane, L.; Baziard-Mouysset, G.; Payard, M., Caignard, D-H.; Rettori, M-C.; Renard, P. Synthesis and pharmacological evaluation of imidazoline sites I1 and I2 selective ligands. Bioorg. Med. Chem., 2001, 9(3), 585-592.
78. Gentili, F.; Bousquet, P.; Carrieri, A.; Feldman, J.; Ghelfi, F.; Giannella, M.; Piergentili, A.; Quaglia, W., Vesprini, C.; Pigini, M. Rational design of the new antihypertensive I1-receptor ligand 2-(2-biphenyl-2-yl-1-methyl-ethyl)-4,5-dihydro-1H-imidazole. Letters in Drug Design and Discovery, 2005, 2, 571-578
79. Treder, A.P.; Andruszkiewicz, R.; Zgoda, W.; Ford, C.; Hudson, A.L. New analogues of agmatine with higher affinity to imidazoline receptors. Bioorg. Med. Chem. Lett., 2009, 19, 1009-1011.
80. Nikolic, K.; Filipic; S.; Agbaba, D. QSAR study of Imidazoline antihypertensive drugs. Bioorg. Med. Chem., 2008, 16, 7134-7140.
81. Nikolic, K.; Filipic, S.; Agbaba, D. QSAR study of selective I1-Imidazoline Receptor Ligands. SAR QSAR Environ. Res., 2008, 20, 133-144.
82. Filipic, S.; Nikolic, K.; Krizman, M.; Agbaba, D. The quantitive structure-retention relationship (QSRR) analysis of some centrally acting antihypertensives and diuretics. QSAR and Combinatorial Science, 2008, 27, 1036-1044.
83. Eric, S.; Pavlovic, M.; Popovi, G., Agbaba D. Study of retention parameters obtained in RP-TLC system and their application on QSAR/QSPR of some alpha adrenergic and imidazoline receptor ligands. J. Chromatogr. Sci., 2007, 45, 140-145.
84. Eric, S.; Solmajer, T; Zupan, J.; Novic, M.; Oblak, M.; Agbaba, D. Prediction of selectivity of 1-adrenergic antagonists by counterpropagation neural network (CP-ANN). Farmaco., 2004, 59(5), 389-395.
85. Eric, S.; Solmajer, T.; Zupan, J.; Novic, M.; Oblak, M., Agbaba, D. Quantitative structure-activity relationships of 1 adrenergic antagonists. J. Mol. Model., 2004, 10(2), 139-50.
86. Vuievi, K.; Popovi, G.; Nikolic, K., Vovk, I.; Agbaba, D. An experimental design approach to selecting the optimum HPLC conditions for the determination of 2-arylimidazoline derivatives. J. Liq. Chromat. Rel. Techn., 2009, 32(5), 656-667.
87. Filipic, S.; Nikolic, K.; Krizman M.; Agbaba, D. Theoretical study of inclusion complexes between-cyclodextrin and guanidine/imidazoline analogs. Drugs Fut., 2008, 33 (Suppl. A) P067: 2008.
88. Filipic, S.; Nikolic, K.; Agbaba, D. Separation and migration behavior of some centrally acting antihypertensives. Arh. Farm., 2010, 60, 912-913.
89. Filipic, S.; Nikolic, K.; Vovk, I.; Krizman, M.; Agbaba, D. The Quantitative Structure-Retention Relationship (QSRR) analysis of some centrally acting antihypertensives and diuretics in cyclodextrin-mediated capillary electrophoresis. Mac. Pharmac. Bull., 2011, 57, Supp II-37.
90. Eric S.; Solmajer, T.; Oblak, M.; Kotnik, M.; Agbaba, D. Modelling of alpha1-adrenergic receptors: The application in the design of selective alpha1b-adrenergic antagonists, D Biopolymers, 2005, 80, 561.
91. Carrieri, A.; Brasili, L.; Leonetti, F., Pigini, M.; Giannella, M.; Bousquet, P.; Carotti, A. 2-D and 3-D modeling of imidazoline receptor ligands: Insights into pharmacophore. Bioorg. Med. Chem., 1997, 5, 843-856.
92. Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M., Giannella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, S.K., Brasili, L. Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem., 1997, 5, 833-841.
93. Pigini, M.; Bousquet, P.; Brasili, L.; Carrieri, A.; Dontenwill, M.; Gentili, F.; Giannella, M.; Leonetti, F; Piergentili, A.; Quaglia, W.; Carotti A. Binding of tracizolines to the imidazoline receptor. Role of lipophilicity in quantitative structure-activity relationship models. Ann. NY Acad. Sci., 1999, 881, 118-122.
94. Nicolotti, O.; Carotti, A.; Carrieri, A.; Pigini, M.; Gentili, F.; Brasili. L.; Giannella, M.; Quaglia, W.; Piergentili, A.; Bousquet, P.; Dontenwill, M. Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands. Med. Chem. Res., 2004, 13, 170-189.
95. Ballesteros, J.; Maeztu, A.I.; Callado, L.F.; Gutiérrez, M.; García-Sevilla, J.A.; Meana, J.J. I2-Imidazoline receptors and monoamine oxidase B enzyme sites in human brain: Covariation with age. Neurosci Let., 2000, 288:135-138.
96. Ruiz, J.; Martin, I.; Callado, L.F.; Meana, J.J.; Barturen, F.; Garcia-Sevilla, J.A., Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease, Neurosci. Let., 1993, 160: 109-112.
97. Ernsberger, P.; Westbrooks, K. L.; Christen, M. O.; Schafer, S.G. A Second Generation of Centrally Antihypertensive Agents Act on Putative I1 Imidazoline Receptor. J. Cardiovasc. Pharmacol., 1992, 20, S1-S10.
98. Langin, D.; Paris, H.; Lafontan, M. Binding of [3H]Idazoxan and of Its Methoxy Derivative [3H]RX821002 in Human Fat Cells: [3H]RX821002 Labels Additional Non-Alpha 2-Adrenergic Binding Sites. Mol. Pharmacol., 1990, 37, 876-885.
99. Chapleo, C.B.; Myers, P.L.; Butler, R.C., Doxey, J.C.; Roach, A.G.; Smith, C.F. Alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants. J. Med. Chem., 1983, 26(6), 823-831.
100. Hudson, A.L.; Chapleo, C.B.; Lewis, J.W.; Husbands, S.; Grivas, K.; Mallard, N.J.; Nutt, D.J. Identification of ligands selective for central I2-imidazoline binding sites. Neurochem. Int., 1997, 30, 47-53.
101. Callado, L.F.; Maeztu, A.I.; Ballesteros, J.; Gutiérrez, M.; Javier Meana, J., Differential [3H]idazoxan and [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I2 receptors in human postmortem frontal cortex. Eur. J. Pharmacol., 2001, 423, 109-114.
102. Giorgioni, G.; Ambrosini, D.; Vesprini, C.; Hudson, A.; Nasuti, C.; Di Stefano, A.; Sozio, P.; Ciampi, O.; Costa, B.; Martini, C.; Carrieri, A.; Carbonara, G.; Enzensperger, C.; Pigini, M. Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI. Bioorg. Med. Chem., 2010, 18, 7085-7091.
103. Tyacke, R.J.; Robinson, E.S.; Nutt, D.J.; Hudson, A.L. 5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: In vitro and in vivo characterisation in rat brain. Neuropharmacology, 2002, 43, 75-83.
104. Touzeau, F.; Arrault, A.; Guillaumet, G.; Scalbert, E.; Pfeiffer, B., Rettori, M-C.; Renard, P.; Merour, J-Y. Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives. J. Med. Chem., 2003, 46(10), 1962-1979.
105. Ruffolo, R.R. Jr.; Waddell, J.E. Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist. J. Pharmacol. Exp. Ther., 1982, 222(1), 29-36.
106. Brasili, L.; Pigini, M.; Marucci, G.; Quaglia, W.; Malmusi, L.; Lanier, S.M.; Lanier, B. Separation of β-adrenergic and imidazoline/guanidinium receptive sites (IGRS) activity in a series of imidazoline analogues of Cirazoline. Bioorg. Med. Chem., 1995, 3, 1503-1509.
107. Gentili, F.; Bousquet, P.; Brasili, L., Caretto, M.; Carrieri, A.; Dontenwill, M.; Giannella, M.; Marucci, G.; Perfumi, M.; Piergentili, A.; Quaglia, W.; Rascente, C.; Pigini M. 2-Adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole. J. Med. Chem., 2002, 45(1), 32-40.
108. Gentili, F.; Cardinaletti, C.; Vesprini, C.; Ghelfi, F.; Farande, A.; Giannella, M.; Piergentili, A.; Quaglia, W.; Mattioli, L.; Perfumi, M.; Hudson, A.; Pigini, M. Novel Ligands Rationally Designed for Characterizing I2-Imidazoline Binding Sites Nature and Functions. J. Med. Chem., 2008, 51, 5130-5134.
109. Pigini, M.; Bousquet, P.; Brasili, L.; Carrieri, A.; Cavagna, R.; Dontenwill, M.; Gentili, F.; Giannella, M.; Leonetti, F.; Piergentili, A.; Quaglia, W.; Carotti, A. Ligand binding to I2 imidazoline receptor: The role of lipophilicity in quantitative structure-activity relationship models. Bioorg. Med. Chem., 1998, 6(12), 2245-2260.
110. Bruban, V.; Feldman, J.; Dontenwill, M.; Greney, H.; Brasili, L.; Giannella, M.; Pigini, M.; Bousquet, P. An unexpected central hypertensive effect of the new imidazoline compound benazoline. Ann. NYAcad. Sci., 1999, 881, 102-105.
111. Baurin, N.; Vangrevelinghe, E.; Morin-Allory, L.; Merour, J.Y.; Renard, P.; Payard, M.; Guillaumet, G.; Marot, C. 3D-QSAR CoMFA study on imidazolinergic I(2) ligands: A significant model through a combined exploration of structural diversity and methodology. J. Med. Chem., 2000, 43(6), 1109-1122.
112. Wikberg, J.E.S.; Hudson, A.L. A series of novel imidazoline I2-receptor selective Schiff bases of 1-(benzylidenamino)-3,3-dimethylguanidine. Neurochem. Int., 1996, 30(1), 95-99.
113. Olmos, G.; Alemany, R.; Boronat, M.A.; Garcia-Sevilla, J.A. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Ann. NY Acad. Sci., 1999, 881, 144-160.
114. Jasper, J.R., Lesnick, J.D., Chang, L.K.; Yamanishi, S.S.; Chang, T.K.; Hsu, S.A.; Daunt, D.A.; Bonhaus, D.W.; Eglen, R.M. Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: Agonist-mediated[35S]GTPgammaS binding. Biochem. Pharmacol., 1998, 55(7), 1035-1043.
115. Brown, C.M.; MacKinnon, A.C.; Redfern, W.S.; Williams, A.; Linton, C.; Stewart, M,; Clague, R.U.; Clark, R.; Spedding, M. RS-45041-190:A selective, high-affinity ligand for I2 imidazoline receptors. Br. J. Pharmacol., 1995, 116(2), 1737-1744.
116. Saczewski, F.; Tabin, P.; Tyacke, R.J.; Maconie, A.; Saczewski, J., Kornicka, A., Nutt, D.J.; Hudson, A.L. 2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic 2 receptor ligands. Bioorg. Med. Chem., 2006, 14, 6679-6685.
117. Glennon, R.A.; Grella, B.; Tyacke, R.J.; Lau, A.; Westaway, J.; Hudson, A.L. Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg. Med. Chem. Lett., 2004, 14(2), 527-529.
118. Dardonville, C.; Fernandez-Fernandez, C.; Gibbons, S.L.; Ryan, G.J.; Jagerovic, N.; Gabilondo, A.M.; Meana, J.J.; Callado, L.F. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the-opioid receptor and I2-imidazoline binding sites. Bioorg. Med. Chem., 2006, 14, 6570-6580.
119. Dardonville, C.; Jagerovic, N.; Callado, L.F.; Meana, J.J. Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: A new series of hybrid molecules with significant binding affinity for-opioid receptors and I2-imidazoline binding sites, Bioorg. Med. Chem. Lett., 2004, 14, 491-493.
120. Chang-Fong, J.; Tyacke, R.J.; Lau, A.; Westaway, J.; Hudson, A.L.; Glennon, R.A. Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I2 receptor ligands, Bioorg. Med. Chem. Lett., 2004, 14, 1003-1005.
121. Lee, J.P.; Chen, W.; Wu, H.T.; Lin, K.C.; Cheng, J.T. Metformin can Activate Imidazoline I-2 Receptors to Lower Plasma Glucose in Type 1-like Diabetic Rats. Horm. Metab. Res., 2011, 43, 26-30.
122. Tonello, R.; Villarinho, J.G.; da Silva Sant'Anna, G., Tamiozzo, L.; Machado, P.; Trevisan, G.; Pinto Martins, M.A.; Ferreira, J.; Rubin, M.A. The potential antidepressant-like effect of imidazoline I2 ligand 2-BFI in mice. Prog. Neuropsychopharm. Biol. Psychiatry, DOI: 10.1016/j.pnpbp.2011.11.005, Article in Press.
123. Li, J.-X.; Zhang, Y.; Winter, J.C. Morphine-induced antinociception in the rat: Supra-additive interactions with imidazoline I2 receptor ligands. Eur. J. Pharmacol., 2011, 669, 59-65.
124. Thorn, D.A.; Zhang, Y.; Peng, B.-W.; Winter, J.C.; Li, J.-X. Effects of imidazoline I2 receptor ligands on morphine-and tramadol-induced antinociception in rats. Eur. J. Pharmacol., 2011, 670, 435-440.
125. Sampson, C.; Zhang, Y.; Bello, F.D.; Li, J.-X. Effects of imidazoline I 2 receptor ligands on acute nociception in rats. NeuroReport, 2012, 23, 73-77.
126. Bhalla, S.; Andurkar, S.V.; Gulati, A. Study of adrenergic, imidazoline, and endothelin receptors in clonidine-, morphine-, and oxycodone-induced changes in rat body temperature. Pharmacology, 2011, 87, 169-179.
127. Li, J.-X.; Zhang, Y. Imidazoline I2 receptors: Target for new analgesics? Eur. J. Pharmacol. 2011, 658, 49-56
128. Clews, J.; Morgan, N.G.; Ramsden, C.A. Preparation of Novel 2-(Benzo[b]furan-2-yl)1Himidazolines for Photoaffinity Labeling and Affinity Isolation of Imidazoline Binding Proteins. J. Heterocyclic Chem., 2001, 38, 519-521.
129. Chan, S.L.; Brown, C.A.; Scarpello, K.E.; Morgan, N.G. The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1-and I2-sites. Br. J. Pharmacol., 1994, 112(4), 1065-1070.
130. Gothert, M.; Bruess, M.; Boenisch, H.; Molderings, G.J. Presynaptic imidazoline receptors: new developments in characterization and classification. Ann. NY Acad. Sci., 1999, 881, 171-184.
131. Morgan, N.G.; Chan, S.L.; Mourtada, M.; Monks, L.K.; Ramsden, C.A. Imidazolines and pancreatic hormone secretion. Ann. NY Acad. Sci., 1999, 881, 217-228.
132. Efendic, S.; Efanov, A.M.; Berggren, P.O.; Zaitsev, S.V. Two generations of insulinotropic imidazoline compounds. Diabetes, 2002, 5 (Suppl. 3): S448-S454.
133. Plant, T.D.; Henquin, J.C. Phentolamine and yohimbine inhibit ATPsensitive K+ channels in mouse pancreatic β-cells. Br. J. Pharmacol., 1990, 101, 115-120.
134. Proks, P.; Ashcroft, F.M. Phentolamine block of KATP channels is mediated by Kir6.2 Proc. Natl. Acad. Sci. USA, 1997, 94, 11716-11720.
135. Mukai, E.; Ishida, H.; Horie, M.; Noma, A.; Seino, Y.; Takano, M. The antiarrhythmic agent cibenzoline inhibits K(ATP) channels by binding to Kir6.2. Biochem. Biophys. Res. Commun., 1998, 251, 477-481.
136. Chan, S.L.F.; Pallett, A.L.; Clews, J.; Ramsden, C.A.; Morgan, N.G. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with a receptors. Eur. J. Pharmacol., 1997, 323, 241-244.
137. Kameda, K.; Ono, S.; Koyama, I.; Abiko, Y. Insulin releasing action of 2-[2-(4,5-dihydro-1H-imadazol-2-yl)-1-phenylethyl] puridine dihydrochloride sesquihydrate (DG-5128), a new, orally effective hypoglycaemic agent. Acta Endocrinol., 1982, 99, 410-415.
138. Kawazu, S.; Suzuki, M.; Watanabe, T.; Ishii, J. Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjects. Diabetes, 1987, 36, 216-220.
139. Kawazu, S.; Suzuki, M.; Negishi, K.; Ishii, J.; Sando, H.; Katagiri, H.; Kanazawa, Y.; Yamanouchi, S.; Akanuma, Y.; Kajinumma, H.; Suzuki, K.; Watanabe, K.; Itoh, T.; Kobayashi, T.; Kosaka, K. Initial phase II clinical studies on midaglizole (DG-5128). A new hypoglycemic agent. Diabetes, 1987, 36, 221-226
140. Efanov, A.M.; Zaitsev, S.V.; Mest, H.J.; Raap, A.; Appelskog, I.B.; Larsson, O.; Berggren, P.O.; Efendic, S. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. Diabetes, 2001, 50, 797-802.
141. Hoy, M.; Olsen, H.L.; Andersen, H.S.; Bokvist, K.; Buschard, K.; Hansen, J.; Jacobsen, P.; Petersen, J.S.; Rorsman, P.; Gromada, J. Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca2+-dependent exocytosis in pancreatic β-and β-cells, Eur. J. Pharmacol., 2003, 466, 213-221.
142. Hoy, M.; Olsen, H.L.; Bokvist, K.; Petersen, J.S.; Gromada, J. The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 368, 284-293.
143. Brenner, M.B.; Gromada, J.; Efanov, A.M.; Bokvist, K.; Mest, H.J. Restoration of first-phase insulin secretion by the imidazoline compound LY374284 in pancreatic islets of diabetic db/db mice. Ann. N Y Acad. Sci., 2003, 1009, 332-340.
144. Grosse-Lackmann, T.; Zunkler, B.J.; Rustenbeck, I. Specificity of nonadrenergic imidazoline binding sites in insulin-secreting cells and relation to the block of ATP-sensitive K+ channels. Ann. N. Y. Acad. Sci., 2003, 1009, 371.
145. Morgan, N.G.; Cooper, E.J.; Squires, P.E.; Hills, C.E.; Parker, C.A.; Hudson, A.L. Comparative Effects of Efaroxan and b-Carbolines on the Secretory Activity of Rodent and Human β-Cells. Ann. N Y Acad. Sci., 2003, 1009, 167-174.
146. Lacombe, C.R.; Viallard, V.P.; Paris, H.J.P. The properties of imidazoline derivatives to stimulate insulin release by hamster pancreatic islets are probably due to 2-adrenoceptor blockade but not to interaction with non-adrenergic idazoxan binding sites. Diabete et Metabolisme, 1993, 19, 381-386.
147. Smith, R.J.; Aston-Jones, G. 2 Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biol. Psychiatry, 2011, 70, 712-719.
148. Gentili, F.; Cardinaletti, C.; Carrieri, A.; Ghelfi, F.; Mattioli, L.; Perfumi, M.; Vesprini, C.; Pigini, M. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur. J. Pharmacol., 2006, 553, 73-81.
149. Boronat, M.A.; Olmos, G.; García-Sevilla, J.A. Attenuation of tolerance to opioid-induced antinociception and protection against morphineinduced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Br. J. Pharmacol., 1998, 125, 175-185.
150. Callado, L.F.; Martín-Gómez, J.I.; Ruiz, J.; Garibi, J.M.; Meana, J.J., Imidazoline I2 receptor density increases with the malignancy of human gliomas. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 785-787.